company background image
GILD

Gilead Sciences SNSE:GILD Stock Report

Last Price

US$65.55

Market Cap

US$102.1b

7D

0%

1Y

0%

Updated

03 Feb, 2023

Data

Company Financials +

GILD Stock Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

GILD fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends1/6

My Notes

New

Notes are coming soon

Gilead Sciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Gilead Sciences
Historical stock prices
Current Share PriceUS$65.55
52 Week HighUS$62.30
52 Week LowUS$57.39
Beta0.43
1 Month Change0%
3 Month Change0%
1 Year Change0%
3 Year Change-6.36%
5 Year Change-17.86%
Change since IPO-13.41%

Recent News & Updates

Recent updates

Shareholder Returns

GILDCL BiotechsCL Market
7D0%0%0%
1Y0%0%0%

Return vs Industry: GILD underperformed the CL Biotechs industry which returned 2.3% over the past year.

Return vs Market: GILD underperformed the CL Market which returned 3.5% over the past year.

Price Volatility

Is GILD's price volatile compared to industry and market?
GILD volatility
GILD Average Weekly Movement0%
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in CL Market0%
10% least volatile stocks in CL Market0%

Stable Share Price: GILD is less volatile than 75% of CL stocks over the past 3 months, typically moving +/- 0% a week.

Volatility Over Time: GILD's weekly volatility (0%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198714,400Dan O'Dayhttps://www.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.

Gilead Sciences, Inc. Fundamentals Summary

How do Gilead Sciences's earnings and revenue compare to its market cap?
GILD fundamental statistics
Market CapUS$102.08b
Earnings (TTM)US$3.33b
Revenue (TTM)US$27.14b

30.6x

P/E Ratio

3.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GILD income statement (TTM)
RevenueUS$27.14b
Cost of RevenueUS$5.64b
Gross ProfitUS$21.50b
Other ExpensesUS$18.16b
EarningsUS$3.33b

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)2.66
Gross Margin79.22%
Net Profit Margin12.29%
Debt/Equity Ratio119.8%

How did GILD perform over the long term?

See historical performance and comparison

Dividends

3.6%

Current Dividend Yield

109%

Payout Ratio